Trial reportSleep2011
A novel nasal expiratory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: a randomized controlled trial.
Trial report in Sleep, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00772044 (Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-blind Study to Compare Safety and Effectiveness of the ProventTM Professional Sleep Apnea Therapy Device to Sham for the Non-invasive Treatment of OSAH
Who cites it
38 citing papers in PubMed.
- Trial
- Expiratory Positive Airway Pressure for Sleep Apnea after Stroke: A Randomized, Crossover Trial.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016Trial
- Pilot study of nasal expiratory positive airway pressure devices for the treatment of childhood obstructive sleep apnea syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2014Trial
- A multicenter evaluation of oral pressure therapy for the treatment of obstructive sleep apnea.Sleep medicine · 2013Trial
- Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA).Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2011Trial
- Effects of Continuous Positive Airway Pressure for Hypertension in Patients with Obstructive Sleep Apnoea: A Structured Narrative Review of Randomised Controlled Trials.Journal of clinical medicine · 2026Review
- Redefining Obstructive Sleep Apnea: Treatment in the Modern Era.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Obstructive sleep apnea-associated hypertensive disorders in pregnancy: a literature review and clinical management strategies.Reproductive biology and endocrinology : RB&E · 2025Review
- Obstructive Sleep Apnea: Strategies for Screening, Management, and Overcoming Treatment Challenges in the Outpatient Setting.American journal of lifestyle medicine · 2025Review
- Development of a guide for continuous positive airway pressure use - A good fit: Making continuous positive airway pressure work for you.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2025Article
- REM-OSA as a Tool to Understand Both the Architecture of Sleep and Pathogenesis of Sleep Apnea-Literature Review.Journal of clinical medicine · 2023Review
- Serendipity.Sleep advances : a journal of the Sleep Research Society · 2023Article
- Quantitative Data Integration Analysis Method for Cross-Studies: Obstructive Sleep Apnea as an Example.Computational and mathematical methods in medicine · 2022Article
- Making Sense of the Noise: Toward Rational Treatment for Obstructive Sleep Apnea.American journal of respiratory and critical care medicine · 2020Article
- Effect of High-Flow Nasal Cannula on Sleep-disordered Breathing and Sleep Quality in Patients With Acute Stroke.Cureus · 2020Article
- REM obstructive sleep apnea: risk for adverse health outcomes and novel treatments.Sleep & breathing = Schlaf & Atmung · 2019Review
- Obstructive Sleep Apnea Screening in Patients With Atrial Fibrillation: Missed Opportunities for Early Diagnosis.Journal of clinical medicine research · 2019Article
- Treatment options for obstructive sleep apnea.Neurology. Clinical practice · 2017Article
- Efficacy of expiratory positive airway pressure nasal device.Sleep & breathing = Schlaf & Atmung · 2016Article
- Expiratory positive airway pressure (EPAP) nasal device therapy: a welcome addition to obstructive sleep apnea syndrome therapy.Sleep & breathing = Schlaf & Atmung · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
objectivesInvestigate the efficacy of a novel nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA).
designA prospective, multicenter, sham-controlled, parallel-group, randomized, double-blind clinical trial.
setting19 sites including both academic and private sleep disorder centers PATIENTS: Obstructive sleep apnea with a pre-study AHI ≥10/hour
interventionsTreatment with a nasal EPAP device (N=127) or similar appearing sham device (N=123) for 3 months. Polysomnography (PSG) was performed on 2 non-consecutive nights (random order: device-on, device-off) at week 1 and after 3 months of treatment. Analysis of an intention to treat group (ITT) (patients completing week 1 PSGs) (EPAP N=119, sham N=110) was performed. MEASUREMENTS AND
resultsAt week 1, the median AHI value (device-on versus device-off) was significantly lower with EPAP (5.0 versus 13.8 events/h, P<0.0001) but not sham (11.6 versus 11.1 events/h, P=NS); the decrease in the AHI (median) was greater (-52.7% vs. -7.3%, P<0.0001) for the ITT group. At month 3, the percentage decrease in the AHI was 42.7% (EPAP) and 10.1% (sham), P<0.0001. Over 3 months of EPAP treatment the Epworth Sleepiness Scale decreased (9.9 ± 4.7 to 7.2 ± 4.2, P<0.0001), and the median percentage of reported nights used (entire night) was 88.2%.
conclusionsThe nasal EPAP device significantly reduced the AHI and improved subjective daytime sleepiness compared to the sham treatment in patients with mild to severe OSA with excellent adherence. CLINICAL TRIAL INFORMATION: REGISTRATIONS: ClinicalTrials.gov. Trial name: Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea (AERO). URL: http://www.clinicaltrials.gov/ct2/show/NCT00772044?term=Ventus&rank=1. REGISTRATION NUMBER: NCT00772044.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.